Shire Hunter syndrome therapy fails to hit study targets
Shire’s investigational Hunter syndrome therapy SHP609 has failed to meet primary and secondary targets in a mid-stage trial.
Read More
Tag: MPS II
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
